Hylafem
Hylafem Uses, Dosage, Side Effects, Food Interaction and all others data.
Hylafem, also known as hydrogen borate, is a weak monobasic Lewis acid of boron with the chemical formula H3BO3. Hylafem is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and eyewashes . It is known to exhibit some antibacterial activity against infections such as bacterial vaginosis and candidiasis .
Hylafem exhibits minimal bacteriostatic and antifungal activities . Hylafem is likely to mediate antifungal actions at high concentrations over prolonged exposures .
| Trade Name | Hylafem |
| Generic | Boric acid |
| Boric acid Other Names | ácido bórico, boracic acid, Boric acid, hydrogen borate, orthoboric acid |
| Weight | +, |
| Type | Vaginal Suppository, Vaginal |
| Formula | BH3O3 |
| Weight | Average: 61.833 Monoisotopic: 62.017524428 |
| Protein binding | No protein binding reported. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
No FDA- or EMA-approved therapeutic indications on its own.
Hylafem is also used to associated treatment for these conditions: Acne, Asthenopia, Ocular Irritation, Skin Mycoses, Eye discomfort, Skin disinfection, Irrigation of the ocular surface therapy
How Hylafem works
Information regarding the mechanism of action of boric acid in mediating its antibacterial or antifungal actions is limited. Hylafem inhibits biofilm formation and hyphal transformation of Candida albicans, which are critical virulence factors . In addition, arrest of fungal growth was observed with the treatment of boric acid .
Toxicity
Acute oral LD50 is 2660 mg/kg in rat . Individuals are likely to be exposed to boric acid from industrial manufacturing or processing. Local tissue injury from boric acid exposure is likely due to caustic effects. Systemic effects from boric acid poisoning usually occur from multiple exposures over a period of days and involve gastrointestinal, dermal, CNS, and renal manifestations. Gastrointestinal toxicity include persistent nausea, vomiting, diarrhea, epigastric pain, hematemesis, and blue-green discoloration of the feces and vomit . Following the onset of GI symptoms, a characteristic intense generalized erythroderma follows . Management of mild to moderate toxicity should be supportive. In case of severe toxicity, dialysis may be required in addition to supportive treatment.
Food Interaction
No interactions found.Volume of Distribution
Volume of distribution ranges from 0.17 to 0.5 L/kg in humans, where large amounts of boric acid are localized in brain, liver, and kidney .
Elimination Route
Hylafem is well absorbed from the gastrointestinal tract, open wounds, and serous cavities but displays limited absorption in intact skin . Following intraperitoneal injection in mice, the peak concentration was reached in about 1.0-1.5 hr in the brain whereas the value was 0.5 hr in other tissues .
Half Life
According to human cases of poisoning, the elimination half-life of boric acid ranges from 13 to 24 hours .
Clearance
A case report of acute boric acid poisoning following oral ingestion of 21 g of boric acid presents the total body clearance of 0.99 L/h before hemodialysis .
Elimination Route
Regardless the route of administration, boric acid predominantly undergoes rapid renal excretion of >90% of total administered dose as unchanged form. Small amounts are also excreted into sweat, saliva, and feces. Following administration as ointment, urinary excretion of boric acid accounted for only 1% of the administered dose .
Innovators Monograph
You find simplified version here Hylafem
